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ORIGINAL ARTICLEInhibitory effect of Lactobacillus plantarum and Lb. fermentum isolated from
the faeces of healthy infants against nonfermentative bacteria causing
nosocomial infectionsM. M. Soltan Dallal1,2, A. Davoodabadi3, M. Abdi4, M. Hajiabdolbaghi5, M. K. Shariﬁ Yazdi6,7, M. Douraghi1,4 and
S. M. Tabatabaei Bafghi1
1) Food Microbiology Research Center, 2) Division of Food Microbiology, Department of Pathobiology, School of Public Health, Tehran University of Medical
Sciences, 3) Department of Microbiology, Medical School, Babol University of Medical Science, Babol, 4) Division of Bacteriology, Department of Pathobiology,
School of Public Health, 5) Department of Infectious and Tropical Diseases, Imam Khomeini Hospital, 6) Zoonosis Research Center and 7) Department of Medical
Laboratory Sciences, School of Para Medicine, Tehran University of Medical Sciences, Tehran, IranAbstractNosocomial infection constitutes a major public health problem worldwide. Increasing antibiotic resistance of pathogens associated with
nosocomial infections has also become a major therapeutic challenge for physicians. Thus, development of alternative treatment
protocols, such as the use of probiotics, matters. The aim of this research was to determine the antagonistic properties of Lactobacillus
plantarum and Lb. fermentum isolated from the faeces of healthy infants against nonfermentative bacteria causing nosocomial infections.
One hundred ﬁve samples of nosocomial infections were collected and processed for bacterial isolation and antimicrobial susceptibility
testing following standard bacteriologic techniques. The antibiotic susceptibility test was performed by the disk diffusion method, and
antagonistic effect of Lactobacillus strains was investigated by well diffusion method. Of 105 samples, a total of 29 bacterial strains were
identiﬁed as nonfermentative bacteria, including 17 Acinetobacter baumannii and 12 Pseudomonas aeruginosa. A. baumannii showed high
resistance to tested antibiotics except ampicillin/sulbactam, and P. aeruginosa showed resistance to ampicillin/sulbactam and gentamicin
and sensitive to amikacin and meropenem. Lb. plantarum had antagonistic properties against both A. baumannii and P. aeruginosa strains.
Lb. plantarum had considerable effects on preventing the growth of A. baumannii and P. aeruginosa strains. However, further research is
needed to better understanding of these effects on P. aeruginosa.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
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E-mail: mkshariﬁyazdi@gmail.comIntroductionNosocomial infections are one of the major problems in hos-
pitals throughout the world. The term “nosocomial” applies to
any infections that develop in a patient during a stay in a hospital
or other clinical facilities which were not present at the time of© 2016 The Author(s). Published by El
This is an oadmission. It may become clinically apparent either during the
hospitalization or after discharge [1]. Nosocomial infections
cause morbidity and mortality, functional disability, emotional
suffering and economic burden among hospitalized patients
[2,3]. Infections such as surgical wound, respiratory, blood-
stream and urinary tract infections are the most common types
of nosocomial infections that occur in hospital settings [4].
Nonfermentative bacteria such as Acinetobacter baumannii and
Pseudomonas aeruginosa play an important role in causing
nosocomial infections [5].
Probiotics are microorganisms that are believed to provide
health beneﬁts for the digestive system when consumed [6]. ANew Microbe and New Infect 2017; 15: 9–13
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boulardii and some other microbes have been proposed as and
are used as probiotic strains, i.e. live microorganisms as a food
supplement to beneﬁt health, such as exerting an antagonistic
effect on the gastroenteric pathogens Clostridium difﬁcile,
Campylobacter jejuni, Helicobacter pylori and rotavirus, neutralizing
food mutagens produced in the colon and lowering serum
cholesterol [7]. Various health and nutritional effects of lactic acid
bacteria have been described, including improvement of the
quality of human and animal foods, metabolic stimulation of the
synthesis of vitamins and enzymes, stabilization of the intestinal
microﬂora, competence with intestinal pathogens, host innate
immune boost, production of antimicrobials, reduction of the
risk of colon cancer by neutralizing carcinogens and suppression
of tumors by modulating the probiotic strains [8,9]. Probiotic
properties are not seen in all strains but rather are seen only in
certain species, depending on the strain [10]. Most bacteria have
developed antibiotic resistance; investing in alternative treat-
ments such as probiotics may help solve this problem.
The aim of this research was to study the effect of Lb.
plantarum and Lb. rhamnosus isolated from the faeces of healthy
infants in reducing the rates of nonfermentative bacteria causing
nosocomial infection.Material and MethodsIn total 105 bacterial samples were collected from Valiasr Hos-
pital Laboratory, Tehran University of Medical Sciences, Tehran,
Iran. These samples were collected from the patients in noso-
comial infection epidemics. All the samples were primarily
investigated for morphologic and biochemical characteristics,
including Gram stain, motility, catalase, oxidation and fermenta-
tion, grown at 42°C, indole and esculin test. The isolated strains
were transferred into tryptic soy broth after adding 15% glycerol
in a 1.5 mL microtube and stored at −20°C. Antimicrobial sus-
ceptibility testing was performed by the agar diffusion method on
Mueller-Hinton agar as recommended by the United States
Clinical and Laboratory Standards Institute (CLSI) [11].
Lactobacillus strains
Lb. plantarum 34-5 and Lb. fermentum 89-1 were isolated from
the faeces of healthy newborns. Identiﬁcation of these two
strains was performed with 16S rDNA gene sequencing. In
brief, genomic DNA was extracted according to a previously
described method [8]. The PCR primer sequences were as
follows: forward primer 50-CTCGTTGCGGGACTTAA-30, and
reverse primer 50-GCAGCAGTAGGGAATCTTC-30 (Bioneer,
Korea). The reaction mixture consisted of 3 pmol primers,
1.5 mM MgCl2, 0.2 mM dNTPs, 2 μL of genomic DNA, 5 μL© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Micr
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/410× PCR buffer and 1.5 U of Taq DNA polymerase (Sinaclon,
Iran) in a ﬁnal volume of 50 μL. The PCR program started with
an initial denaturation at 94°C for 2 minutes, followed by 30
cycles of 94°C for 30 seconds, 53°C for 1 minute and 72°C for
1 minute [12]. PCR products were separated by agarose gel
electrophoresis (1.5% w/v) and visualized by staining with
ethidium bromide. The PCR products of strains were sent to a
sequencing company (Bioneer, Korea), and the 16S rDNA se-
quences were compared to known sequences in GenBank using
the Basic Local Alignment Search Tool (BLAST; http://www.
ncbi.nlm.nih.gov/blast).
Antagonistic test
To test the antagonistic effect of Lactobacillus, the nonfermentative
isolates were ﬁrst cultured on MacConkey and then on nutrient
agar. The Lactobacillus strains were inoculated into de Man,
Rogosa and Sharpe (MRS) broth and incubated in anaerobic jar at
37°C for 24 hours. On the surface of nutrient agar plate, holes
5 mm in diameter and depth were created under sterile condi-
tions using a Pasteur pipette. Then, using a sterile swab, non-
fermentative bacteria of 1/10 McFarland dilutions were inoculated
into the surface of nutrient agar. The MRS broth containing
Lactobacillus was centrifuged at 6000 rpm for 10 minutes. Su-
pernatant was ﬁltered with a bacteriologic ﬁlter. Then 100 μL of
solution of each of lactobacilli was poured into a separate well.
The media were kept in the refrigerator for 2 hours until the
liquid was absorbed, then transferred into the incubator and
incubated for 14 to 15 hours at 37°C. After incubation, the
diameter of the inhibition zones (mm) around the well was
measured using a ruler. The antagonistic effect of lactobacillus
against nonfermentative isolates was interpreted on the bases of
inhibitory growth zones as follows: negative (−), <11 mm; me-
dium (+), 11 to 16 mm; strong (++), 17 to 22 mm; and very
strong (+++), >22 mm [9]. Standard Lb. rhamnosus GG, obtained
from the Department of Microbiology, School of Health, Tehran
University of Medical Sciences, was used as a control.
Statistical analysis
Data of each assay were analysed by one-way analysis of vari-
ance by SAS 9.2 software (SAS Institute, Cary, NC, USA).
Comparison among treatment means was performed using
Duncan’s new multiple range test. Differences were considered
signiﬁcant at P < 0.05.ResultsOf 105 samples, a total of 29 were identiﬁed as non-
fermentative bacteria, including 17 A. baumannii and 12
P. aeruginosa. Table 1 shows the antimicrobial susceptibilityobiology and Infectious Diseases, NMNI, 15, 9–13
.0/).
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was seen except ampicillin/sulbactam, and 100% resistance to
cotrimoxazole was observed. P. aeruginosa showed resistance
to ampicillin/sulbactam and gentamicin and was sensitive to
amikacin and meropenem (Tables 2 and 3). Lb. plantarum andTABLE 1. Antimicrobial resistance patterns of Acinetobacter
baumannii isolates
Antibiotic
Resistant
abundance,
n (%)
Intermediate
abundance,
n (%)
Sensitive
abundance,
n (%)
Amikacin, 30 μg 13 (76.47) 1 (5.88) 3 (17.64)
Ciproﬂoxacin, 5 μg 16 (94.11) 1 (5.88) —
Piperacillin/tazobactam, 100/10 μg 14 (82.35) 2 (11.76) 1 (5.88)
Cotrimoxazole, 25 μg 17 (100) — —
Meropenem, 10 μg 15 (88.23) — 2 (11.76)
Ampicillin/sulbactam, 10/10 μg 8 (47.05) 1 (5.88) 8 (47.05)
Ceftriaxone, 30 μg 17 (100) — —
Ceftazidime, 30 μg 15 (88.23) — 2 (11.76)
TABLE 2. Antimicrobial resistance patterns of Pseudomonas
aeruginosa isolates
Antibiotic
Resistant
abundance,
n (%)
Intermediate
abundance,
n (%)
Sensitive
abundance,
n (%)
Amikacin, 30 μg 2 (16.66) 3 (25) 7 (58.33)
Ciproﬂoxacin, 5 μg 5 (41.66) 2 (16.66) 5 (41.66)
Piperacillin/tazobactam, 100/10 μg 6 (50) — 6 (50)
Gentamycin, 10 μg 9 (75) — 3 (25)
Meropenem, 10 μg 6 (50) — 6 (50)
Ampicillin/sulbactam, 10/10 μg 11 (91.66) — 1 (8.33)
Ceftriaxone, 30 μg 7 (58.33) 1 (8.33) 4 (33.33)
Ceftazidime, 30 μg 7 (58.33) — 5 (41.66)
TABLE 3. Inhibition zone in susceptibility testing of Acinetobacter b
Isolate
Ceftazidime
30 μg
Ceftriaxone
30 μg
Ampicillin/sulbactam
10/10 μg
Meropenem
10 μg
Gentam
10 μg
1 11 7 16 9 NA
2 10 8 17 9 NA
3 12 8 17 11 NA
4 12 6 10 12 NA
5 11 5 9 9 NA
6 10 6 16 11 NA
7 18 6 17 6 NA
8 13 7 17 6 NA
9 10 5 10 6 NA
10 11 6 9 10 NA
11 10 7 7 9 NA
12 10 8 9 8 NA
13 19 6 11 7 NA
14 9 5 8 8 NA
15 12 5 16 16 NA
16 13 6 18 17 NA
17 11 9 7 9 NA
18 14 12 8 15 11
19 13 10 9 13 10
20 13 10 8 20 8
21 19 15 7 13 8
22 19 21 6 19 10
23 18 21 15 22 15
24 12 10 7 14 9
25 11 11 9 14 8
26 19 13 10 19 7
27 13 22 9 20 17
28 11 21 8 21 17
29 11 11 8 13 9
NA, not applicable.
© 2016 The Author(s). Published by Elsevier Ltd on beha
This is an oLb. rhamnosus had antagonistic properties on both A. baumannii
and P. aeruginosa (Table 4). All the tested Lactobacillus strains
had a signiﬁcant antagonistic effect on A. baumannii. Lb. planta-
rum 34-5 had a more powerful effect compared to the other
lactobacilli (Table 4). All the tested lactobacilli isolates had a
signiﬁcant antagonistic effect on P. aeruginosa. Lb. plantarum 34-
5 had more powerful effect compared to the other lactobacilli
(Table 5). The inhibition zones of A. baumannii and P. aeruginosa
isolates by lactobacilli are shown in Figs. 1 and 2.DiscussionEradication and treatment of infections caused by P. aeruginosa
and A. baumannii are difﬁcult because of their high resistance toaumannii and Pseudomonas aeruginosa (mm)
icin Cotrimoxazole
25 μg
Piperacillin/tazobactam
100/10 μg
Ciproﬂoxacin
5 μg
Amikacin
30 μg
8 12 10 13
8 11 10 12
7 12 11 12
9 18 9 9
8 13 11 13
9 12 13 14
10 19 10 15
5 21 12 11
9 14 10 17
6 15 8 18
5 12 10 14
5 11 11 12
8 14 16 13
7 13 11 11
7 12 12 10
5 11 10 18
6 14 10 9
NA 14 17 18
NA 13 13 19
NA 14 14 12
NA 21 21 21
NA 21 22 19
NA 22 18 20
NA 23 15 15
NA 14 21 18
NA 13 14 15
NA 13 22 14
NA 21 14 16
NA 22 22 18
TABLE 4. Antagonistic effect (inhibition zone) of Lactobacillus
fermentum 89-1, Lb. plantarum 34-5 and Lb. rhamnosus GG
against Acinetobacter baumannii isolates
Lactobacillus genus
Antagonistic effect (inhibition zone)a
by abundance, n (%)
− + ++ +++
plantarum 34-5 — 7 (41.17) 10 (58.82) —
fermentum 89-1 — 14 (82.35) 3 (17.64) —
rhamnosus GG — 15 (88.23) 2 (11.76) —
aInhibitory growth zones were interpreted as follows: negative (−), <11 mm; me-
dium (+), 11–16 mm; strong (++), 17–22 mm; and very strong (+++), >22 mm.
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TABLE 5. Antagonistic effect (inhibition zone) of Lactobacillus
fermentum 89-1, Lb. plantarum 34-5 and Lb. rhamnosus GG
against Pseudomonas aeruginosa isolates
Lactobacillus genus
Antagonistic effect (inhibition zone)a
by abundance, n (%)
− + ++ +++
plantarum 34-5 1 (8.33) — 10 (83.33) 1 (8.33)
fermentum 89-1 1 (8.33) 9 (75) 2 (16.66) —
rhamnosus GG 1 (8.33) 3 (25) 8 (66.66) —
aInhibitory growth zones were interpreted as follows: negative (−), <11 mm; me-
dium (+), 11–16 mm; strong (++), 17–22 mm; and very strong (+++), >22 mm.
FIG. 1. Inhibition zone of Acinetobacter baumannii caused by Lactoba-
cillus spp. (Top left) Lb. fermentum 89-1 (16 mm). (Top right) Inhibition
zone of A. baumannii caused by Lb. plantarum 34-5 (19 mm). (Bottom)
Lb. rhamnosus GG (17 mm).
FIG. 2. Inhibition zone of P. aeruginosa caused by Lactobacillus spp. (Top
left) Lb. fermentum 89-1 (20 mm). (Top right) Inhibition zone of
P. aeruginosa caused by Lb. plantarum 34-5 (24 mm). (Bottom) Lb.
rhamnosus GG (22 mm).
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serious infections in hospitalized patients because they can
grow under a variety of different conditions and have acquired
widespread antibiotic resistance. They therefore result in
important nosocomial infections that impose high costs on
healthcare [15]. Lactobacilli are harmless microorganisms
capable of producing acid secretion, bacteriocins and other by-
products that can neutralize some pathogens, can regulate the
inﬂammatory response of the immune system and can be used
in the treatment of gastrointestinal disorders [16,17].
Our results showed that lactobacilli had an inhibition growth
effect on both A. baumannii and P. aeruginosa. These results are
in agreement with previously reported ﬁndings that different
strains of lactobacilli inhibit the growth of bacteria such as
Staphylococcus aureus, Escherichia coli, P. aeruginosa, Klebsiella
pneumoniae, and Burkholderia cepacia [18,19]. Others have re-
ported that lactobacilli had an inhibitory effect on the growth of
both Gram-negative and Gram-positive bacteria [20]. In addi-
tion, there is also in vitro report of probiotics against pathogenic
bacteria [21]. Several previous studies have shown that pro-
biotic production factors other than lactic acid, such as bacte-
riocins, proteinase, peroxidase and exopolysaccharide, can
exert antibacterial effects [18]. Some studies have reported that
lactobacilli such as Lb. plantarum, Lb. paracasei, Lb. fermentum,
Lb. bokash and Lb. boots isolated from the faeces of infants had
inhibitory activity against food-contaminated bacteria such as
E. coli, S. aureus, Yersinia enterocolitica and Bacillus cereus [9,22]. A
previous study demonstrated the antibacterial effect of Lacto-
bacillus isolated from breast milk against the gastrointestinal
pathogenic bacteria E. coli, Shigella, Pseudomonas and Salmonella
[22]. Another study found that strains of lactobacilli lower the
effect of production of elastase and bioﬁlm formation [15].ConclusionThe lactobacilli had good effects on preventing the growth of
A. baumannii and P. aeruginosa. These results are in agreement
with other published reports from different countries that
indicate that infection control efforts may be achieved with
probiotic bacteria. We believe that more attention should be
paid to these areas, particularly to create a standardized
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